backBrazil’s health regulator Anvisa has barred the entry of several so-called “weight-loss pens,” GLP-1–based products that lack authorization to be sold or used in the country. The ban covers items such as T.G. 5, Lipoless, Lipoless Éticos, Tirzazep Royal Pharmaceuticals and T.G. Indufar, following growing evidence of illegal sales and advertising, including online promotion. The agency emphasized that medicines without Brazilian registration may only be imported under exceptional circumstances, strictly for personal use and with a medical prescription; however, when Anvisa issues a specific prohibition, even this limited form of importation is no longer allowed.
The decision aims to prevent misuse and protect public health, since unapproved products have not had their quality, safety or effectiveness evaluated in Brazil. Anvisa also highlighted the dangers of medicines that lack proper traceability, come with foreign-language instructions or may be subject to counterfeiting or adulteration, all of which increase the risk of harm to patients and undermine regulatory oversight. The agency further noted that, for approved medications, the holder of the registration is responsible for ensuring legal distribution and addressing any unexpected issues related to their use.
share
